Related Experiment Video
Updated: Jan 31, 2026
In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
Salmonella Bacteria Membrane-Fusion Paclitaxel Loaded Liposomes for Enhanced Therapy of Intraperitoneal Metastatic
Wei Duan1,2, Chujie Li1,2, Yang Xia1,2
1School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen, China.
Abstract:
Ovarian cancer (OvCa) remains a leading cause of gynecological cancer mortality, particularly due to its aggressive peritoneal metastasis. Conventional treatments, including surgery and paclitaxel-based chemotherapy, are often limited by poor drug penetration into solid tumors, multidrug resistance, and the highly immunosuppressive tumor microenvironment. To overcome these challenges, we engineered a novel bacteria membrane-fused biomimetic paclitaxel liposome (PLip@DMV) by incorporating bacteria membrane-derived vesicles from attenuated Salmonella VNP20009. Administered via intraperitoneal injection, PLip@DMV not only delivered paclitaxel effectively but also leveraged the immunomodulatory properties of the Salmonella membrane. This led to significant antitumor immune activation within the metastatic tumor microenvironment, synergistically enhancing therapeutic efficacy and markedly prolonging the survival of tumor-bearing mice. Furthermore, the enhanced delivery efficiency and sustained-release characteristics of PLip@DMV resulted in significantly reduced systemic toxicity and tissue accumulation compared to free paclitaxel. Our findings demonstrate that PLip@DMV represents a more efficient, safer, and immunologically potentiated strategy for treating peritoneal metastatic ovarian cancer. This novel biomimetic nanocarrier holds significant promise for improving clinical outcomes in advanced OvCa.
Insights
A novel biomimetic liposome loaded with paclitaxel (PLip@DMV) effectively targets ovarian cancer metastasis. This innovative treatment enhances antitumor immunity and reduces toxicity, offering a promising strategy for advanced ovarian cancer.
Area of Science:
- Oncology
- Nanotechnology
- Immunotherapy
Background:
- Ovarian cancer (OvCa) is a leading cause of gynecological cancer mortality, often characterized by aggressive peritoneal metastasis.
- Conventional treatments face challenges like poor drug penetration, multidrug resistance, and an immunosuppressive tumor microenvironment.
- Developing novel therapeutic strategies is crucial for improving outcomes in advanced OvCa.
Purpose of the Study:
- To engineer a novel bacteria membrane-fused biomimetic paclitaxel liposome (PLip@DMV) for treating peritoneal metastatic ovarian cancer.
- To evaluate the efficacy of PLip@DMV in enhancing drug delivery, activating antitumor immunity, and reducing systemic toxicity.
- To assess the potential of PLip@DMV as an improved therapeutic strategy for advanced OvCa.
Main Methods:
- Engineered PLip@DMV by incorporating bacteria membrane-derived vesicles from attenuated Salmonella VNP20009.
- Administered PLip@DMV via intraperitoneal injection in a mouse model of peritoneal metastatic OvCa.
- Assessed drug delivery, antitumor immune activation, therapeutic efficacy, survival rates, and systemic toxicity.
Main Results:
- PLip@DMV demonstrated effective paclitaxel delivery and leveraged Salmonella membrane properties for immunomodulation.
- Significant antitumor immune activation was observed within the metastatic tumor microenvironment.
- PLip@DMV synergistically enhanced therapeutic efficacy, markedly prolonged survival, and reduced systemic toxicity and tissue accumulation compared to free paclitaxel.
Conclusions:
- PLip@DMV represents a more efficient, safer, and immunologically potentiated strategy for treating peritoneal metastatic ovarian cancer.
- The biomimetic nanocarrier enhances drug delivery and sustained release, leading to improved therapeutic outcomes.
- PLip@DMV holds significant promise for improving clinical outcomes in patients with advanced OvCa.
Related Concept Videos
01:43SNAREs and Membrane Fusion
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:26Fusion of Secretory Vesicles with the Plasma Membrane
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Plasma Membrane in Bacteria and Archaea
02:45Nuclear Fusion
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...